ALTIMMUNE, INC. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
ALTIMMUNE, INC. (ALT) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $6.18 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2023-02-28
- ALTIMMUNE, INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2022-12-31 was $0.00.
- ALTIMMUNE, INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2022-09-30 was $0.00.
- ALTIMMUNE, INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2022 was $6.18M.
- ALTIMMUNE, INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2020 was $13.63M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $6.18M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $6.18M 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $6.18M 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $13.63M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |